GlassScriptPhysician profile
Brianne M Gupta
NPI 1750660882
$3,033.14
in general payments reported to CMS, 2019-2025
33 companies · $496 in 2025
The $496 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,084 · 2022: $593 · 2023: $372 · 2024: $489 · 2025: $496.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,357.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,356.59 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,137.59 | 2021-2025 | |
| Pfizer INC. | $220.89 | 2021-2023 | |
| Allergan, INC. | $155.66 | 2021-2022 | |
| Biohaven Pharmaceuticals, INC. | $129.04 | 2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $121.33 | 2021-2023 | Xifaxan |
| Boehringer Ingelheim Pharmaceuticals, INC. | $117.25 | 2021-2022 | |
| Solta Medical, A Division of Bausch Health US, LLC | $114.47 | 2025 | Clear+Brilliant |
| Bayer Healthcare Pharmaceuticals INC. | $111.71 | 2021-2022 | |
| Lilly USA, LLC | $88.78 | 2022-2023 | Mounjaro |
| Novo Nordisk INC | $88.73 | 2021-2023 | |
| Novartis Pharmaceuticals Corporation | $80.36 | 2022-2025 | |
| Biohaven Pharmaceutical Holding Company LTD. | $78.68 | 2022 | |
| Revance Therapeutics, INC. | $56.60 | 2025 | Daxxify |
| Horizon Therapeutics Plc | $51.44 | 2021-2022 | |
| Kowa Pharmaceuticals America, INC. | $50.80 | 2022 |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mylan Specialty L.P. | $49.07 | 2024 | Yupelri |
| Antares Pharma, INC. | $39.54 | 2021-2022 | |
| Esperion Therapeutics, INC. | $33.50 | 2021 | |
| Merck Sharp & Dohme LLC | $31.46 | 2021-2022 | |
| Amgen INC. | $30.93 | 2021-2023 | Repatha |
| Eisai INC. | $28.32 | 2021 | |
| Astrazeneca Pharmaceuticals LP | $28.28 | 2021-2022 | |
| Boston Scientific Corporation | $20.28 | 2022 | |
| Sunovion Pharmaceuticals INC. | $19.98 | 2021 | |
| Arbor Pharmaceuticals, INC. | $19.18 | 2021 | |
| Janssen Pharmaceuticals, INC | $18.84 | 2023 | Xarelto |
| Jazz Pharmaceuticals INC. | $17.74 | 2021 | |
| Organogenesis INC. | $17.32 | 2021 | |
| Abbott Laboratories | $16.09 | 2021 | |
| Supernus Pharmaceuticals, INC. | $15.23 | 2022 | Tlando, Xyosted |
| Halozyme INC | $15.10 | 2023 | |
| Glaxosmithkline, LLC. | $14.81 | 2022 | |
| Gilead Sciences, INC. | $14.14 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Brianne Gupta listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.